Splenopentin

What is Splenopentin?

Splenopentin (SP-5) is a 5-residue peptide derived from splenopoietin, the spleen-derived peptide first characterized as the splenic counterpart to thymopoietin (the thymic peptide that gives rise to the thymopentin TP-5 active fragment). The molecule was characterized in the late 1980s and 1990s as part of the broader investigation into thymic and splenic peptide immunomodulators. Singh and Biswas's 1998 Immunology Research review (PMID 9638477) consolidated splenopentin alongside thymopentin as paired immunomodulatory pentapeptides — the splenic and thymic complements within the broader 'small immunomodulatory peptide' framework that emerged from Allan Goldstein's thymic-peptide research program. The Bräuer 1993 Agents and Actions paper (PMID 8317333) characterized thymic and splenic immunomodulatory peptide effects in antigen-induced arthritis in rats. Splenopentin has not been clinically translated and is not FDA-approved for any indication; it is sold through some research-channel sources for laboratory use and remains a research-tier compound conceptually parallel to thymopentin within the historical immunomodulatory peptide landscape.

What Splenopentin Is Investigated For

Splenopentin is a research-tier immunomodulatory peptide topic, not a clinical therapy. The molecule was characterized as the splenic counterpart to the thymic-origin thymopentin (TP-5), with paired immunomodulatory effects on T-cell function in animal and cell-culture models. The Singh 1998 Immunology Research review (PMID 9638477) is the standard reference framing splenopentin and thymopentin as paired immunomodulatory pentapeptides within the broader Goldstein thymic-and-splenic peptide research program. Splenopentin has not advanced to clinical translation and is not FDA-approved for any indication. The molecule has remained research-tier throughout its commercial history and has been substantially overshadowed even within the niche thymic-and-splenic peptide framework by thymopentin (which reached limited non-U.S. clinical use as Timunox) and by thymosin alpha-1 (which has 35+ country approvals as Zadaxin). For patients, the practical takeaway is that splenopentin is interesting historical immunomodulator biology with no contemporary clinical role.

How It Works

Splenopentin is the spleen-version of thymopentin — both are tiny 5-amino-acid pieces of larger immune-regulating proteins (one from the thymus, one from the spleen). They were studied in the 1980s and 1990s as broad-spectrum immune modulators. Neither one has FDA approval. Splenopentin is even more obscure than thymopentin and is essentially a research-only peptide. Modern targeted biologic drugs that hit specific immune molecules (like TNF or IL-6 inhibitors) have largely replaced this older class of broad-spectrum immunomodulator peptides.

Splenopentin (SP-5) is a 5-residue peptide derived from splenopoietin, the spleen-derived peptide characterized as conceptually parallel to the thymic-derived thymopoietin in the broader investigation of small organ-specific immunomodulatory peptides through the 1980s and 1990s. The pentapeptide retains the immunomodulatory activity of the parent splenopoietin in cell-culture and animal models of immune function, with effects on T-cell maturation and cytokine production characterized alongside thymopentin in the broader Singh-and-Biswas framework. The 1993 Bräuer Agents and Actions paper (PMID 8317333) extended the research to thymic and splenic peptide effects in antigen-induced arthritis. The 1998 Singh Immunology Research review (PMID 9638477) consolidated splenopentin and thymopentin as paired immunomodulators within the historical thymic-and-splenic peptide framework. The mechanism is broad-spectrum immunomodulation rather than specific cytokine or receptor targeting — a framework that has been substantially superseded by modern targeted biologic immunotherapy in contemporary clinical practice.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Splenopentin:

• 01Modern characterization of splenopentin pharmacology beyond the historical 1980s-1990s framework
• 02Whether splenopentin retains any niche clinical role in the modern targeted-immunotherapy landscape

Forms & Administration

Splenopentin is a research peptide with no clinical formulation or FDA approval. Synthetic splenopentin is sold by some research-chemical suppliers for laboratory use.

Common Questions

Who Splenopentin Is NOT For

Drug & Supplement Interactions

No validated drug-interaction profile. Theoretical concurrent-immunomodulator effects with biologic immunotherapy or other immune-modulating agents are uncharacterized.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions